[HTML][HTML] Sleep assessment in a population-based study of chronic fatigue syndrome
ER Unger, R Nisenbaum, H Moldofsky, A Cesta… - BMC neurology, 2004 - Springer
Background Chronic fatigue syndrome (CFS) is a disabling condition that affects approximately
800,000 adult Americans. The pathophysiology remains unknown and there are no …
800,000 adult Americans. The pathophysiology remains unknown and there are no …
[HTML][HTML] Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative
X Li, A Cesta, M Movahedi, C Bombardier - Arthritis Research & Therapy, 2022 - Springer
Background The prevalence of rheumatoid arthritis (RA) in persons 60 years or older is
estimated to be 2%. Late-onset rheumatoid arthritis (LORA) is traditionally defined as the onset of …
estimated to be 2%. Late-onset rheumatoid arthritis (LORA) is traditionally defined as the onset of …
Frailty and risk of osteoporotic fractures in patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative
The evidence assessing the relationship between frailty and risk of adverse health outcomes
in patients with rheumatoid arthritis (RA) remains limited and sparse in the literature. Data …
in patients with rheumatoid arthritis (RA) remains limited and sparse in the literature. Data …
ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)
JE Pope, M Movahedi, E Rampakakis, A Cesta… - RMD open, 2018 - rmdopen.bmj.com
Objective(s) This study evaluated the interaction of anticitrullinated protein antibody (ACPA)
and rheumatoid factor (RF) in predicting sustained clinical response in an observational …
and rheumatoid factor (RF) in predicting sustained clinical response in an observational …
[HTML][HTML] Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: results from the Ontario Best Practices …
…, R Joshi, E Rampakakis, C Thorne, A Cesta… - Medicine, 2019 - journals.lww.com
Access to care and management of Rheumatoid Arthritis (RA) patients may differ based on
residential area. We described differences in the profile of patients initiating their first biologic …
residential area. We described differences in the profile of patients initiating their first biologic …
[HTML][HTML] Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort
M Movahedi, A Cesta, X Li, C Bombardier… - Plos one, 2022 - journals.plos.org
Objectives Disease activity status described at fixed time points does not accurately reflect
disease course in chronic and relapsing diseases such as rheumatoid arthritis (RA). We …
disease course in chronic and relapsing diseases such as rheumatoid arthritis (RA). We …
Toward defining primary and secondary nonresponse in rheumatoid arthritis patients treated with anti-TNF: results from the BioTRAC and OBRI registries
…, E Rampakakis, M Movahedi, A Cesta… - The Journal of …, 2020 - jrheum.org
Objective. Although most patients with rheumatoid arthritis (RA) respond to anti–tumor necrosis
factor (anti-TNF) treatment, some present with initial nonresponse (1ry nonresponse) or …
factor (anti-TNF) treatment, some present with initial nonresponse (1ry nonresponse) or …
Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative
V Ahluwalia, E Rampakakis, M Movahedi, A Cesta… - Clinical …, 2017 - Springer
Despite the availability of treatment guidelines and effective treatments, real-world effectiveness
remains suboptimal partly due to poor patient medication adherence. We evaluated a …
remains suboptimal partly due to poor patient medication adherence. We evaluated a …
Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada
M Movahedi, D Choquette, L Coupal, A Cesta, X Li… - BMJ open, 2023 - bmjopen.bmj.com
Objectives The similarity in retention of tumour necrosis factor inhibitors (TNFi) and tofacitinib
(TOFA) was previously reported separately by the Ontario Best Practices Research …
(TOFA) was previously reported separately by the Ontario Best Practices Research …
Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: results from a real-world rheumatoid …
M Movahedi, E Hepworth, R Mirza, A Cesta… - Seminars in Arthritis and …, 2020 - Elsevier
Objectives Time to discontinuation of biologic therapy may be related to mechanism of action.
We aimed to compare discontinuation of tumor necrosis factor inhibitors (TNFi) versus non-…
We aimed to compare discontinuation of tumor necrosis factor inhibitors (TNFi) versus non-…